Will Aviva’s share price ever go back up to 400p?

The Aviva share price has underperformed the FTSE 100 in the stock market crash. But could it deliver an impressive return for buyers today?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Aviva (LSE: AV) shares were well above 400p coming into 2020. They’re now trading at 280p (down 33%), compared with a 22% fall for the FTSE 100. There’s potential for an impressive return for buyers of the stock today. But will Aviva’s share price ever go back up to 400p?

Fellow FTSE 100 firm Smiths Group (LSE: SMIN) has performed rather better than both Aviva and the index. Even after a 7.5% fall to 1,325p following its annual results today, its share price is down a relatively creditable 21% for the year. Could today’s dip be a good opportunity to snap up shares in this market outperformer?

Smart move

Smiths reported a 2% rise in revenue from continuing operations for its financial year ended 31 July. However, operating profit was down 11%. The engineering conglomerate accepted temporarily higher costs to maintain “exemplary customer service” during the challenging second half of the year. It looks to have paid off, because it’s already been rewarded with further contract wins.

The board declared a total dividend of 35p per share for the year, reflecting a delayed interim dividend of 11p and proposed final dividend of 24p. Shareholders will welcome the return of the dividend, albeit at a 24% lower level than last year. For buyers of the stock today, a 2.6% yield isn’t to be sniffed at.

Attractive proposition for investors

Smiths’ planned demerger of its medical division was put on hold in March. I’ve long believed the separation of this business could unlock value for shareholders. As such, I was pleased management’s intent to separate the division remains unchanged.

Why the fall in the share price? I think part of the reason may be that the company told us revenue from continuing operations for the four months to the end of August is running 8% down against pre-pandemic comparators.

However, I continue to see the group’s highly-differentiated, market-leading products and services, and its positioning in long-term growth markets, as a very attractive proposition for investors. As such, I rate the stock a ‘long-term buy’.

Aviva’s share price is cheap!

Amanda Blanc was appointed CEO of Aviva in July. She’s already waded into the market to buy shares. And it was some purchase. A cool £1m for 324,887 shares at a price of 307.8p.

Now, most companies these days require their CEOs to build a shareholding to some percentage of their basic salary. This is 300% of £1m in Blanc’s case, Aviva noting, “she will be required to retain 50% of the net share releases from her deferred bonus and LTIP awards until this requirement is met.”

I’d say the fact she hasn’t hung around, but immediately bought a shedload of shares in the market, tells us she reckons they’re currently cheap. What’s more, buyers today are getting them even cheaper!

Can Aviva’s share price return to 400p?

I’ve been impressed by Blanc, and her clear-sighted strategy. This has only been enhanced in my eyes by the recent £1.6bn sale of a majority shareholding in Aviva Singapore.

Despite the cash raised, I still think the company will rebase its ordinary dividend later this year. However, with the stock trading at a 40% discount to the group’s last reported net asset value, and on a single digit earnings multiple, I reckon the shares are indeed cheap. So cheap, I’d buy them for a return to 400p+.

G A Chester has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Are Tesco shares easy money heading into 2026?

The supermarket industry is known for low margins and intense competition. But analysts are bullish on Tesco shares – and…

Read more »

Smiling black woman showing e-ticket on smartphone to white male attendant at airport
Investing Articles

Can this airline stock beat the FTSE 100 again in 2026?

After outperforming the FTSE 100 in 2025, International Consolidated Airlines Group has a promising plan to make its business more…

Read more »

Investing Articles

1 Stocks and Shares ISA mistake that will make me a better investor in 2026

All investors make mistakes. The best ones learn from them. That’s Stephen Wright’s plan to maximise returns from his Stocks…

Read more »

Portrait Of Senior Couple Climbing Hill On Hike Through Countryside In Lake District UK Together
Investing Articles

I asked ChatGPT if £20,000 would work harder in an ISA or SIPP in 2026 and it said…

Investors have two tax-efficient ways to build wealth, either in a Stocks and Shares ISA or SIPP. Harvey Jones asked…

Read more »

Investing Articles

How much would I need invested in an ISA to earn £2,417 a month in passive income?

This writer runs the numbers to see what it takes in an ISA to reach £2,417 a month in passive…

Read more »

Investing Articles

Rolls-Royce shares or Melrose Industries: Which one is better value for 2026?

Rolls-Royce shares surged in 2025, surpassing most expectations. Dr James Fox considers whether it offers better value than peer Melrose.

Read more »

Investing Articles

3 top Vanguard ETFs to consider for an ISA or SIPP in 2026

Edward Sheldon believes that these three Vanguard ETFs could be solid investments for a pension (SIPP) or investment account in…

Read more »

Investing Articles

5 growth stocks on Dr James Fox’s watchlist for 2026

Dr James Fox believes these UK and US growth stocks are worth considering as he looks to outperform the stock…

Read more »